The Memo: InkSpace Imaging Transforming MRI with Patient-Centered Innovation

Under the direction of President and CEO Peter Fischer, InkSpace Imaging is pioneering a breakthrough in MRI technology with ultralight, flexible, body-conforming MRI coils. The company was initially focused on pediatrics, addressing a long-standing gap in MRI accessibility and patient comfort for children, who often require sedation due to poorly fitting, rigid coils. Building on this foundation, InkSpace Imaging has expanded its product line, securing FDA clearance for adult MRI applications as well, bringing the same advancements in comfort and imaging quality to a broader patient population.

By replacing uncomfortable, one-size-fits-all coils with customized, high-performance solutions, InkSpace Imaging is improving image quality, reducing scan times, and enhancing patient comfort — all while making MRI more efficient for hospitals and healthcare providers. Its coils are plug-and-play compatible with Siemens, GE, and Philips MRI systems, requiring no workflow or software modifications. Additionally, they fit seamlessly into current reimbursement models, making adoption straightforward for hospitals and imaging centers.

With FDA-cleared products, a strategic partnership with Siemens, and a growing presence with GE and Philips, InkSpace Imaging is rapidly scaling. As the company expands globally, it continues to demonstrate how innovation in MRI coils can optimize patient care, streamline workflows, and increase hospital efficiency.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-inkspace-imaging-transforming-mri-with-patient-centered-innovation 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more